Novartis' malaria drug enters phase 3

Editor’s note: Fierce’s PM Tracker will not publish November 24th and 25th in observance of the U.S. Thanksgiving holiday. We’ll be back in your inboxes Monday, November 28.

Today's Big News

Nov 23, 2022

Philips adds another 91 deaths to toll from ventilator recall, bringing total to 260

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Racing rising resistance, Novartis marches malaria therapy into phase 3

Senate bill seeks to improve Medicare handbook amid spike in marketing complaints

Teva, AbbVie's Allergan lock in $6.6B deal to settle thousands of US opioid lawsuits

Mirati is once again the subject of Big Pharma takeover talks : report

 

Featured

Philips adds another 91 deaths to toll from ventilator recall, bringing total to 260

Nearly a year-and-a-half into Philips’ recall of about 5.5 million of its CPAP and BiPAP machines and other respiratory devices, complaints about the affected machines are still rolling in.
 

Top Stories

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

CSL Behring and uniQure's newly approved hemophilia B gene therapy, Hemgenix, comes with an eye-popping price tag of $3.5 million. The one-time treatment can replace regular prophylactic infusions of factor IX replacement therapy for patients.

Racing rising resistance, Novartis marches malaria therapy into phase 3

Novartis and Medicines for Malaria Venture have hit go on the phase 3 development of a novel combination therapy, hustling the solid dispersion formulation toward the final R&D hurdle on the strength of evidence it may kill drug-resistant forms of the parasite.

Senate bill seeks to improve Medicare handbook amid spike in marketing complaints

New legislation aims to improve the Medicare & You handbook to help better inform seniors about the differences between traditional Medicare and Medicare Advantage.

Teva, AbbVie's Allergan lock in $6.6B deal to settle thousands of US opioid lawsuits

Teva and AbbVie's Allergan this week locked in a combined $6.6 billion in settlements to resolve allegations that they helped fuel the U.S.' opioid epidemic by overstating the painkillers’ benefits, downplaying the risk of addiction and failing to maintain controls to prevent opioid misuse.

Mirati is once again the subject of Big Pharma takeover talks: report

Discussions surrounding the acquisition of Mirati have reignited, according to a new report from Bloomberg. The San Diego biotech is working with an advisor and large pharmas are considering the financial details, although no formal offer has been made, according to the outlet.

Could $250 Apple AirPods disrupt the OTC hearing aid market? One study shows it’s possible

The study pitted the second-generation version of the original AirPods and the more advanced AirPods Pro against basic and premium models of currently available hearing aids.

Walmart healthcare exec Pegus departs for Morgan Health

Pegus, who served as Walmart's executive vice president for health and wellness, will join the healthcare arm of JPMorgan Chase as a managing director.

2 years after rejection, Mesoblast touts long-term cell therapy survival data as key to FDA resubmission

Mesoblast has established another pillar of the evidence it thinks will support a second run at the FDA, touting long-term data from the study at the center of its rejected application as the key to its planned resubmission.

On a roll, Takeda's dengue vaccine shifts into FDA's fast review lane

Three months after gaining its first worldwide approval for its dengue fever vaccine, Takeda is progressing toward a blessing from the FDA. As the European Commission is expected to hand out an approval, the shot has received a priority review from the FDA.

SPAC again: NewAmsterdam takes blank-check route to fund phase 3 trials for Amgen offcast

Once the hottest ticket for an ambitious biotech to go public, special purpose acquisition company (SPAC) deals almost died out earlier in the year. But there has been a steady trickle in recent months, with NewAmsterdam Pharma Co. the latest to take the blank-check route.

Viz.ai’s deep learning AI spots suspected aortic dissections with high accuracy: study

When put to the test, the algorithm was able to correctly detect aortic dissections with about 94% sensitivity and to exclude negative cases with more than 97% specificity.

Fierce Healthcare Fundraising Tracker—DispatchHealth rakes in $330M; Care.ai banks $27M for ambient intelligence

The Fierce Healthcare fundraising tracker keeps tabs on health tech and digital health financing rounds.
 
Fierce podcasts

Don't miss an episode

'Podnosis': How public-private employer coalitions can force innovation, and how to fix the healthcare system

This week on "Podnosis," we discuss the challenges companies face in trying to provide healthcare coverage for their workers. We also talk about how to fix the broken healthcare system.
 

Resources

Whitepaper

Enhance the cost-effectiveness of your chemical supply chain

Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific.
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.
Webinar

Webinar: Writing the Future of Antibody Discovery Solutions

Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions.

Whitepaper

Commercializing Gene Therapies – Supply Chain Considerations

This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success.
Video

Discover why you should choose the Gibco™️ Efficient-Pro™️ system

Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video.